Xinxiang Tuoxin Pharmaceutical Co.Ltd. (SHE:301089) — Market Cap & Net Worth
Market Cap & Net Worth: Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)
Xinxiang Tuoxin Pharmaceutical Co.Ltd. (SHE:301089) has a market capitalization of $404.05 Million (CN¥2.76 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #13483 globally and #4029 in its home market, demonstrating a 0.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s stock price CN¥21.82 by its total outstanding shares 126544500 (126.54 Million). Review Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) total liabilities to assess the company's total debt and financial obligations.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Market Cap History: 2021 to 2026
Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s market capitalization history from 2021 to 2026. Data shows change from $1.47 Billion to $404.05 Million (-5.56% CAGR).
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.37x
Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s market cap is 1.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.47 Billion | $502.48 Million | $65.71 Million | 2.93x | 22.37x |
| 2022 | $1.32 Billion | $784.72 Million | $286.54 Million | 1.68x | 4.60x |
| 2023 | $993.65 Million | $835.51 Million | $243.07 Million | 1.19x | 4.09x |
| 2024 | $522.01 Million | $421.69 Million | -$19.88 Million | 1.24x | N/A |
| 2025 | $518.49 Million | $378.34 Million | -$69.66 Million | 1.37x | N/A |
Competitor Companies of 301089 by Market Capitalization
Companies near Xinxiang Tuoxin Pharmaceutical Co.Ltd. in the global market cap rankings as of June 19, 2026.
Key companies related to Xinxiang Tuoxin Pharmaceutical Co.Ltd. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Historical Marketcap From 2021 to 2026
Between 2021 and today, Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s market cap moved from $1.47 Billion to $ 404.05 Million, with a yearly change of -5.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥404.05 Million | -22.07% |
| 2025 | CN¥518.49 Million | -0.67% |
| 2024 | CN¥522.01 Million | -47.47% |
| 2023 | CN¥993.65 Million | -24.59% |
| 2022 | CN¥1.32 Billion | -10.38% |
| 2021 | CN¥1.47 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Xinxiang Tuoxin Pharmaceutical Co.Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $404.05 Million USD |
| MoneyControl | $404.05 Million USD |
| MarketWatch | $404.05 Million USD |
| marketcap.company | $404.05 Million USD |
| Reuters | $404.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; an… Read more